Quick answer
Extended answer
How do Semaglutide and Liraglutide compare?
Key facts
- Both class
- Selective GLP-1R agonist (acylated)
- Semaglutide half-life
- ≈ 1 week
- Liraglutide half-life
- ≈ 13 hours
- Semaglutide acylation
- C18 di-acid, γGlu-2xOEG spacer
- Liraglutide acylation
- C16 mono-acid, γGlu spacer
Scientific overview
Liraglutide was the first once-daily acylated GLP-1 receptor agonist. Semaglutide is its long-acting successor, engineered with a longer fatty-acid modification and spacer to support once-weekly kinetics.[2] Both were developed within the same programme and share the core GLP-1(7-37) backbone with modifications.[1]
Mechanism comparison
Receptor pharmacology at GLP-1R is very similar between the two. Both engage Gαs → cAMP → PKA/EPAC2 signalling, produce glucose-dependent insulinotropic and glucagonostatic effects, slow gastric emptying and act on central appetite pathways. The principal pharmacological difference is exposure profile driven by acylation chemistry.
| Feature | Semaglutide | Liraglutide |
|---|---|---|
| Backbone | Modified GLP-1(7-37) | Modified GLP-1(7-37) |
| DPP-4 resistance | Aib8 substitution | No Aib8 substitution (relies on acylation for DPP-4 shielding + albumin binding) |
| Acylation site | Lys26 | Lys26 |
| Fatty-acid chemistry | C18 di-acid (octadecanedioic) | C16 mono-acid (palmitic) |
| Linker | γGlu + 2×OEG (2-[2-(2-aminoethoxy)ethoxy]acetyl) | γGlu |
| Result | ≈ 1 week plasma half-life | ≈ 13 h plasma half-life |
Receptor selectivity
Both are selective at GLP-1R with no pharmacologically meaningful activity at GIPR or GCGR. This distinguishes both from dual (Tirzepatide) and triple (Retatrutide) agonists.
Pharmacokinetic comparison
| Parameter | Semaglutide | Liraglutide |
|---|---|---|
| Plasma half-life (SC) | ≈ 1 week | ≈ 13 hours |
| Dosing frequency | Once weekly (SC); once daily (oral, with SNAC) | Once daily (SC) |
| Time to steady state | ≈ 4–5 weeks | ≈ 2 days |
| Albumin binding | > 99% | > 98% |
| Clearance | Proteolysis; renal/faecal metabolite excretion | Proteolysis; renal/faecal metabolite excretion |
Research applications comparison
| Research area | Semaglutide | Liraglutide |
|---|---|---|
| Type 2 diabetes | SUSTAIN-6 (CV outcomes) | LEADER (CV outcomes) |
| Obesity | STEP programme | SCALE programme |
| Cardiovascular outcomes | SUSTAIN-6, SELECT | LEADER |
| Renal outcomes | FLOW | LEADER renal secondary endpoints |
| Head-to-head evidence | vs Liraglutide (PIONEER 4, oral) | vs Semaglutide (PIONEER 4) |
Human evidence
Liraglutide's cardiovascular outcome evidence derives from LEADER,[9] Semaglutide's from SUSTAIN-6.[6] Head-to-head data comparing oral Semaglutide with subcutaneous Liraglutide were reported in PIONEER 4.[10]
Preclinical evidence
Both compounds have detailed published preclinical characterisation at GLP-1R. Receptor pharmacology is fundamentally similar; the acylation-driven differences appear primarily as pharmacokinetic and biodistribution differences.
Advantages and limitations
- Semaglutide — advantages: once-weekly kinetics; larger and more recent human evidence base; oral formulation.
- Semaglutide — limitations: longer time to steady state; more sensitive assay methodology.
- Liraglutide — advantages: shorter time to steady state; well-established once-daily kinetics; long real-world evidence.
- Liraglutide — limitations: daily dosing burden; smaller more recent evidence base than Semaglutide.
Research-use framing
Related reading: Semaglutide monograph, Albumin binding and half-life extension, Semaglutide pharmacokinetics, GLP-1 receptor explained and SUSTAIN-6.
References10
- 1.
Lau J, Bloch P, Schäffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.
- 2.
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide.. Frontiers in Endocrinology. 2019;10:155.
- 3.
Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist for glycemic control and weight loss.. Cell Metabolism. 2022;34(9):1234-1247.e9.
- 4.
Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.
- 5.
Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity (STEP 1).. New England Journal of Medicine. 2021;384(11):989-1002.
- 6.
Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).. New England Journal of Medicine. 2016;375(19):1834-1844.
- 7.
Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).. New England Journal of Medicine. 2021;385(6):503-515.
- 8.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).. New England Journal of Medicine. 2022;387(3):205-216.
- 9.
Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER).. New England Journal of Medicine. 2016;375(4):311-322.
- 10.
Pratley R, Amod A, Hoff ST, et al.. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4).. Lancet. 2018;394(10192):39-50.
Evidence summary
Research limitations
- Head-to-head evidence is limited to a small number of trials, one of which used oral Semaglutide vs SC Liraglutide.
- In-vitro potency between acylated peptides is highly sensitive to albumin and plasticware.
- Approved-therapeutic clinical data do not describe or endorse research-use scenarios.
- What is Semaglutide?
Beginner-friendly research-focused introduction to Semaglutide — a long-acting GLP-1 receptor agonist derived from native GLP-1(7-37).
- Semaglutide Mechanism of Action
Receptor-level explanation of Semaglutide's activity at GLP-1R — Gαs / cAMP / PKA / EPAC2 signalling, β-arrestin recruitment, insulinotropic and glucagonostatic effects, gastric emptying and central appetite modulation.
- Semaglutide FAQ
Comprehensive research-focused FAQ on Semaglutide — identity, receptor pharmacology, structural modifications, pharmacokinetics, laboratory handling, evidence base and regulatory status.
- Semaglutide Pharmacokinetics
Reported pharmacokinetics of Semaglutide — half-life, albumin binding, C18 di-acid acylation, absorption for subcutaneous vs oral formulations, distribution, steady state and research limitations.
- Semaglutide Research Applications
Overview of published Semaglutide research contexts — metabolic, cardiovascular, renal, neuroinflammation/CNS and NAFLD/MASH — with a clear preclinical vs human evidence split.
- Albumin Binding and Half-Life Extension
Reusable mechanism guide explaining how fatty-acid acylation supports reversible non-covalent binding to serum albumin, and how that extends the plasma half-life of GLP-1 peptides.
Research use only
Publication information
- Published
- 2026-10-15
- Updated
- 2026-10-15
- Reviewed
- 2026-10-15
- Version
- 1.0
Revision history
- v1.02026-10-15· Editorial Team
Authority Sprint 2D — initial publication of GLP-1 comparison guides.
Editorial standards
Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.
Conflict of interest
Next scheduled review: 2028-04-15. Our research methodology describes how the review is conducted.